World Pharmaceutical Contract Manufacturing Market

http://www.reportlinker.com/p098296/World-Pharmaceutical-Contract-Manufacturing--Market.html

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in Millions of US$. The Major product segments anaylzed are Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 84 companies including many key and niche players worldwide such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd., HAUPT Pharma AG, Jubilant Organosys Ltd., Kemwell Pvt. Ltd., NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd., and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources

PHARMACEUTICAL CONTRACT MANUFACTURING MCP-1535 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. Market Dynamics II-1 An Insight into the Rise of PCM II-1 Industry Potential II-1

2. Service Overview II-3 Introduction II-3 Injectables (injections, vials, and IV solutions) II-3 Solid Dosage Forms (SDFs) (Tablets and Capsules) II-3 Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-4 A Focus on Bio-Manufacturing II-4

3. Trends & Issues II-5 Outsourcing Emerges as a Strategic Priority for Pharmaceutical Companies II-5 Asia Dominates Regional Growth, North America Retains Position as Largest Market II-5 Virtual Pharma vs. Blockbuster Model II-6 Investment Risks in Pharmaceutical Contract Quality Assurance Risk II-6 Drug Development Risk II-6 Acquisition Risk II-6 Client Dependency Risk II-6

4. Recent Industry Activity II-7 Jubilant Acquires Draxis for US$ 253 Million II-7 JHP Acquires Assets of King Pharmaceuticals II-7 NextPharma Acquires Bioserv Corporation II-7 Dr. Reddy's to Acquire Dowpharma's Facilities II-8 PharmAthene to Acquire Avecia's Biodefense Vaccine Operations II-8 Bioserv Enters into an Outsourcing Agreement with BioLife Solutions II-9 Eden Biodesign and Stealthyx Therapeutics Ink an Agreement II-9 NPIL Pharma to Expand HPS Sites in Scotland II-9 Dishman Pharma Installs New API Facilities II-9 Patheon Divests Niagara-Burlington Manufacturing Business to Pharmetics II-10 Jubilant Organosys Acquires Hollister-Stier Laboratories II-10 Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie II-10 Meda Acquires Recip II-11 Keata Pharma to Acquire Pfizer's Production Facility in Canada II-11 STADA Acquires MAKIZ II-12 Nextpharma to Expand its Cytostatics Production Facility II-12 Haupt Pharma Establishes Production Facility in Malta II-12 Kemwell Pockets Pfizer's Uppsala Sweden Based Manufacturing Plant II-13 Crucell and DSM Biologics Enter into a Licensing Agreement with UMN Pharma II-13 Lannett Inks a Multi-Product Contract Manufacturing Agreement with Wintac II-13 ATOZ Establishes Soft Gelatin Manufacturing Facility in Himachal Pradesh, India II-14 BASF Buys Orgamol SA II-14 Federa Completes Construction of Prefilled Syringes Facility II-14 BioProgress PLC Signs an Agreement with Custom Pharmaceuticals II-14 Safeguard Scientifics Acquires Laureate II-14 Patheon Buys MOVA Pharmaceutical II-14 Nichi-iko Strikes a Deal with Maruko Pharmaceutical II-15 DRAXIS Health Acquires Minority Stake in DRAXIS Pharma II-15 WPCC Receives FDA Acceptance II-15 Dechra Pharmaceuticals Acquires Anglian Pharma II-15

5. Focus on Select Global Players II-16 Althea Technologies (USA) II-16 Catalent Pharma Solutions (USA) II-16 Dishman Pharmaceuticals and Chemicals Ltd (India) II-16 HAUPT Pharma AG (Germany) II-16 Jubilant Organosys Ltd (India) II-17 Kemwell Pvt. Ltd (India) II-17 NextPharma (UK) II-17 Nipro Corp (Japan) II-17 Patheon, Inc. (Canada) II-17 Penn Pharmaceutical Services Ltd (UK) II-18 Royal DSM N.V. (Netherlands) II-18

6.